FY26 Revenue Crosses ₹700 Crore Mark
In respect of the entire fiscal year FY26, consolidated turnover generated by the company was ₹704.48 crore, against ₹645.71 crore in the preceding fiscal year, representing a growth rate of 9.10% on a yearly basis.
Consolidated EBITDA grew from ₹123.97 crore in the previous year to ₹131.14 crore, marking an increase of 5.78%. In FY26, consolidated profit before tax was ₹115.63 crore, against ₹109.19 crore during the previous year.
Consolidated net profit of the company grew by 6.74% to ₹87.89 crore, against ₹82.35 crore in the previous year. The earnings per share for FY26 were ₹43.88 against ₹41.11 in FY25.
Company Targets ₹1,000 Crore Revenue in 3 Years
Lincoln Pharmaceuticals reiterated its ambitious growth roadmap and said it is targeting revenue of ₹1,000 crore within the next three years. The growth strategy is backed by expansion into high-value product categories and entry into new markets.
The company aims to achieve annual growth of 15–18%, supported by strong performance across cardiac, diabetic, dermatology and ENT segments.
Global Expansion Plans Gain Momentum
The pharmaceutical company currently exports products to more than 60 countries and plans to expand its international footprint to nearly 90 countries over the next two to three years.
Recently, the company entered the Canadian market and also received approvals from TGA Australia and EU GMP, strengthening its regulated market presence.
CRISIL Reaffirms ‘A/Stable’ Rating
In a further positive development, CRISIL Ratings on January 9 reaffirmed the company’s ratings at ‘CRISIL A/Stable/CRISIL A1’ on its bank facilities.
The rating agency cited the promoters’ extensive industry experience, established market position and healthy financial profile, while also noting challenges related to working capital intensity, regulatory requirements and competition.
FII Holding Increases in March Quarter
Foreign institutional investor holding in the company increased to 5.20% as of March 31, 2026, compared to 5% a year earlier. Domestic institutional investor holding stood at 1.08%.
Greenx Wealth Multihorizons Opportunity Fund held a 1.07% stake in the company, while Rimo Capital Fund LP owned 1.33%.
Lincoln Pharmaceuticals Share Price Gains
Shares of Lincoln Pharmaceuticals ended 1.43% higher at ₹758.15 on May 27, 2026, compared to the previous close of ₹747.45, as investors reacted positively to the company’s earnings performance, dividend announcement and long-term growth guidance.
About Lincoln Pharmaceuticals
Lincoln Pharmaceuticals is engaged in the development and manufacturing of pharmaceutical formulations across multiple therapeutic segments including anti-infective, respiratory, cardio, CNS, anti-diabetic and gynaecology products.
The company operates manufacturing facilities in Gujarat certified under international quality standards and continues to strengthen its presence in domestic and global markets.
